| Editas Medicine: A Cautionary Tale for Investors |
Explore the exciting world of Editas Medicine (EDIT 1.09%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! |
fool.com |
2025-05-15 23:30:00 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) |
Editas Medicine, Inc. (NASDAQ:EDIT ) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Welcome to the last fireside for day 1 of the 2025 Bank of America Healthcare Conference. Thanks for joining this session with Editas. |
seekingalpha.com |
2025-05-14 18:17:01 |
Czytaj oryginał (ang.) |
| Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June |
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy. |
globenewswire.com |
2025-05-14 13:31:00 |
Czytaj oryginał (ang.) |
| Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting |
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia |
globenewswire.com |
2025-05-14 11:01:00 |
Czytaj oryginał (ang.) |
| Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? |
Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year. |
zacks.com |
2025-05-13 14:46:30 |
Czytaj oryginał (ang.) |
| Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y |
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates. |
zacks.com |
2025-05-13 13:45:50 |
Czytaj oryginał (ang.) |
| Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting |
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice |
globenewswire.com |
2025-05-13 11:01:00 |
Czytaj oryginał (ang.) |
| Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates |
Editas Medicine (EDIT) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.76 per share a year ago. |
zacks.com |
2025-05-12 22:45:39 |
Czytaj oryginał (ang.) |
| Editas Medicine Announces First Quarter 2025 Results and Business Updates |
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week |
globenewswire.com |
2025-05-12 20:30:00 |
Czytaj oryginał (ang.) |
| Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board |
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board's (PTABs) previous decision and remanded it back to the PTAB for further review in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier and the Broad Institute (Broad). The Company's in-licensed patents covering CRISPR/Cas12a are not at issue in the interference and are unaffected by this decision. |
globenewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? |
Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-12 17:00:43 |
Czytaj oryginał (ang.) |
| Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May |
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. |
globenewswire.com |
2025-05-05 20:01:00 |
Czytaj oryginał (ang.) |
| Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting |
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. |
globenewswire.com |
2025-04-28 20:31:00 |
Czytaj oryginał (ang.) |
| Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? |
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-04-04 16:35:35 |
Czytaj oryginał (ang.) |
| Editas Medicine Announces Chief Financial Officer Transition |
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. |
globenewswire.com |
2025-03-20 18:01:00 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript) |
Editas Medicine, Inc. (NASDAQ:EDIT ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good morning, everyone. My name is Gena Wang, I'm [Indiscernible] at Biotech Analyst at the Barclays. |
seekingalpha.com |
2025-03-11 18:07:26 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript) |
Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore O'Neill with us. |
seekingalpha.com |
2025-03-10 14:19:04 |
Czytaj oryginał (ang.) |
| Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down |
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates. |
zacks.com |
2025-03-06 13:10:36 |
Czytaj oryginał (ang.) |
| Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates |
Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.23 per share a year ago. |
zacks.com |
2025-03-05 20:25:32 |
Czytaj oryginał (ang.) |
| Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates |
On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-end On track to establish one additional target cell type/tissue by year-end Strong cash position with operational runway into the second quarter of 2027 |
globenewswire.com |
2025-03-05 18:05:00 |
Czytaj oryginał (ang.) |
| Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March |
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward. |
globenewswire.com |
2025-02-24 11:00:00 |
Czytaj oryginał (ang.) |
| Editas And Intellia: Strategic Shifts And Long-Term Investment Potential |
Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided. |
seekingalpha.com |
2025-01-17 14:20:11 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript) |
Editas Medicine, Inc. (NASDAQ:EDIT ) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burkly - Executive Vice President and Chief Scientific Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Brian Cheng Good morning. Thanks for joining us for another session at the 43rd JPMorgan Healthcare Conference. |
seekingalpha.com |
2025-01-15 18:35:19 |
Czytaj oryginał (ang.) |
| Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities |
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non-human primates editing hematopoietic stem cells (HSCs) and liver cells and in vivo delivery data in humanized mice to two additional target cell types. |
globenewswire.com |
2025-01-13 11:00:00 |
Czytaj oryginał (ang.) |
| Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company's President and CEO Gilmore O'Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. |
globenewswire.com |
2025-01-06 11:00:00 |
Czytaj oryginał (ang.) |
| EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce |
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%. |
zacks.com |
2024-12-16 13:45:16 |
Czytaj oryginał (ang.) |
| Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 |
On Thursday, Editas Medicine Inc. EDIT announced a strategic realignment to focus on in vivo gene editing. |
benzinga.com |
2024-12-13 08:44:40 |
Czytaj oryginał (ang.) |
| Editas to reduce about 65% of its workforce over the next six months |
Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies that edit genes within the body. |
reuters.com |
2024-12-12 20:03:18 |
Czytaj oryginał (ang.) |
| Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years |
CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced a critical pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the Company to accelerate its intent to achieve in vivo human proof of concept in approximately two years. |
globenewswire.com |
2024-12-12 18:00:00 |
Czytaj oryginał (ang.) |
| Editas Stock Rises on Updated Data From SCD Study of Reni-Cel |
EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD. |
zacks.com |
2024-12-10 14:15:21 |
Czytaj oryginał (ang.) |
| Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting |
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. |
globenewswire.com |
2024-12-09 14:00:00 |
Czytaj oryginał (ang.) |
| Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? |
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-04 14:36:53 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript) |
Editas Medicine, Inc. (NASDAQ:EDIT ) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore's Healthcare Conference. |
seekingalpha.com |
2024-12-04 00:52:49 |
Czytaj oryginał (ang.) |
| Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts |
BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term. |
benzinga.com |
2024-11-25 14:59:00 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript) |
Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour. |
seekingalpha.com |
2024-11-19 21:53:15 |
Czytaj oryginał (ang.) |
| Editas Medicine to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: |
globenewswire.com |
2024-11-06 11:00:00 |
Czytaj oryginał (ang.) |
| Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y |
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same. |
zacks.com |
2024-11-05 14:05:17 |
Czytaj oryginał (ang.) |
| Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates |
Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago. |
zacks.com |
2024-11-04 11:41:09 |
Czytaj oryginał (ang.) |
| Editas Medicine Announces Third Quarter 2024 Results and Business Updates |
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia |
globenewswire.com |
2024-11-04 09:30:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline |
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-25 15:06:24 |
Czytaj oryginał (ang.) |
| EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down |
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development. |
zacks.com |
2024-10-23 16:30:26 |
Czytaj oryginał (ang.) |
| EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies |
Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading. |
zacks.com |
2024-10-22 16:35:23 |
Czytaj oryginał (ang.) |
| Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript |
Editas Medicine, Inc. (NASDAQ:EDIT ) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief Executive Officer Linda Burkly - Chief Scientific Officer Erick Lucera - Chief Financial Officer Baisong Mei - Chief Medical Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Gena Wang - Barclays Jack Allen - Baird Yanan Zhu - Wells Fargo Soumit Roy - Jones Brian Cheng - JPMorgan Chase Joon Lee - Truist Dae Gon Ha - Stifel Alec Stranahan - Bank of America Rick Bienkowski - Cantor Phil Nadeau - TD Cowen Liisa Bayko - Evercore Mani Foroohar - Leerink Partners Timur Ivannikov - Raymond James Operator Good morning, everyone, and thank you for joining Editas Medicine's Strategic Update Webinar. This webinar is being recorded and can be accessed in the future through this same link or through the Investor section of the company's website. |
seekingalpha.com |
2024-10-22 15:45:03 |
Czytaj oryginał (ang.) |
| Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics |
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine's CRISPR Cas12a genome editing systems with Genevant's proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas' upregulation strategy. |
globenewswire.com |
2024-10-21 20:30:00 |
Czytaj oryginał (ang.) |
| Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept |
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. |
globenewswire.com |
2024-10-18 20:01:00 |
Czytaj oryginał (ang.) |